Alcon has completed its acquisition of Ivantis, gaining rights to the Hydrus microstent in the process, according to a press release.
“We believe this transaction will further strengthen our global surgical portfolio and help provide a platform for more growth in the glaucoma space,” David Endicott, CEO of Alcon, said in the release. “As we welcome Ivantis associates into Alcon, we look forward to introducing Hydrus microstent on a broader, global scale in the near future to help even more patients see brilliantly.”
The microstent is indicated to reduce IOP (Read more...)